A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 249 participants.

Also called NCT06438172

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 249 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06438172
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06438172. Randomized; double masking; primary purpose treatment. Start 2024-03-25 (actual); primary completion 2024-12-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension
Acronym
HM_APOLLO
Condition
Hypertension
Intervention (Drug)
HCP1803-3
Intervention (Drug)
RLD2001-1
Intervention (Drug)
HPP2003-3
Intervention (Drug)
HPP2002-1
Lead sponsor
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct06438172
Content hash
29bfa48cf7c28e64f70ee432c2e20b79b73196427d3405787f6d92c5486df111